HRS9531 clinical trials
How each study uses HRS9531 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS9531 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- HRS9531 Tablet
- 3
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test HRS9531, phase 3 first.
- Oct 2027A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsPhase 3 · Fujian Shengdi Pharmaceutical Co., Ltd.
- May 2027A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusPhase 2 · Fujian Shengdi Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses HRS9531 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsRecruitingPhase 3Fujian Shengdi Pharmaceutical Co., Ltd.NCT07670884Written as HRS9531 Tablet
- A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusRecruitingPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT07599410Written as HRS9531 Tablet
- A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy ParticipantsNot yet recruitingPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT06506175Written as HRS9531 tablets
- Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight SubjectsRecruitingPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT07150962Written as HRS-9531 Tablet
- Efficacy and Safety of HRS9531 Tablet in Obese SubjectsCompletedPhase 2Fujian Shengdi Pharmaceutical Co., Ltd.NCT06841445Written as HRS9531 Tablet
- Mass Balance Study of [14C]HRS9531 in Healthy Male SubjectsCompletedPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT06855147Written as [14C]HRS9531